News Center

Australian EpiTan company has applied for new international patents for all the sustained-release dosage forms of its leading product Melanotan, The patent application covers a variety of existing sustained-release dosage forms, including subcutaneous imp

U.S. FDA approves Vyleesi (Bremelanotide) for use in hyposexuality in premenopausal women

Acetyl Hexapeptide-8, Argireline, Cosmetic peptide

copper peptide, GHK-Cu, cosmetic peptide, AHK-Cu manufacturer

Palmitoyl pentapeptide-4, cosmetic peptide, Palmitoyl Pentapeptide-3